Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences:
馬薩諸塞州劍橋，2024年9月10日 /PRNewswire/ — Blueprint Medicines Corporation（納斯達克股票代碼：BPMC）今天宣佈將參加以下即將舉行的虛擬投資者會議：
- Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.
- TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.
- Stifel 2024 免疫學和炎症虛擬峯會將於 2024 年 9 月 17 日星期二美國東部時間下午 2:00 舉行。
- TD Cowen的慢性蕁麻疹峯會將於美國東部時間2024年9月20日星期五上午11點舉行。
A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at . A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.
每場演講的網絡直播將通過訪問Blueprint Medicines網站的 「投資者與媒體」 欄目進行直播，網址爲。每次演講結束後，網絡直播的重播將在Blueprint Medicines的網站上存檔30天。
About Blueprint Medicines
關於藍圖藥物
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家全球性、完全整合的生物製藥公司，致力於發明改變生活的藥物。我們尋求通過解決兩個核心重點領域的重要醫療問題來減輕人類痛苦：過敏/炎症和腫瘤學/血液學。我們的方法首先是針對疾病的根本原因，運用我們核心重點領域的深厚科學知識和跨多種治療模式的藥物研發專業知識。我們在兩種獲批藥物方面有着良好的成功記錄，其中包括我們爲美國和歐洲的系統性肥大細胞增多症（SM）患者提供的Ayvakit/Ayvakyt（阿伐替尼）。利用我們既有的研究、開發、商業能力和基礎設施，我們現在的目標是通過推進從早期科學到包括Sm和慢性蕁麻疹、乳腺癌和其他實體瘤在內的肥大細胞疾病的高級臨床試驗等廣泛項目來顯著擴大我們的影響力。欲了解更多信息，請在 X（前身爲 Twitter；@BlueprintMeds）和 LinkedIn 上訪問並關注我們。
SOURCE Blueprint Medicines Corporation
來源藍圖藥品公司
譯文內容由第三人軟體翻譯。
